Akari Therapeutics (AKTX)
NASDAQ: AKTX
· Real-Time Price · USD
1.37
-0.03 (-2.14%)
At close: May 02, 2025, 3:59 PM
1.35
-1.46%
After-hours: May 02, 2025, 04:05 PM EDT
-2.14% (1D)
| Bid | 1.2 |
| Market Cap | 19.78K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.79M |
| EPS (ttm) | -2.58 |
| PE Ratio (ttm) | -0.53 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.38 |
| Volume | 6,545 |
| Avg. Volume (20D) | 30,277 |
| Open | 1.37 |
| Previous Close | 1.40 |
| Day's Range | 1.37 - 1.37 |
| 52-Week Range | 0.85 - 4.40 |
| Beta | 0.58 |
About AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous p...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 6, 2014
Employees 8
Stock Exchange NASDAQ
Ticker Symbol AKTX
Website https://www.akaritx.com
1 month ago
+20%
Akari Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
